Astellas Misses Again On Xospata Label Expansion Effort

 
• By Joseph Haas

A Phase III disappointment in a maintenance therapy setting for FLT3-mutated acute myeloid leukemia is yet another failed attempt by Astellas to add to Xospata’s label since US FDA approval in 2018.

Astellas Northbrook, IL
Astellas still has other avenues to label expansion for Xospata • Source: Shutterstock

More from Clinical Trials

More from R&D